

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor: **Ralph A. Cowden III**

Application Number: **10/571,740**

Filing Date: **11/23/2007**

Atty. Docket No.: **4396-060415**

Confirmation No.: **6915**

Group Art No.: **1612**

Examiner: **Milligan, Adam C.**

Title: **NUTRITIONAL SUPPLEMENT AND PROTOCOL**

Commissioner of Patents
Washington, D.C.

DECLARATION OF RALPH A. COWDEN III UNDER 27 CFR § 1.132

I, Ralph A. Cowden III, hereby swear and state as follows:

1. I am president and founder of Med Five, Inc., the Applicant herein. I have personal knowledge of the matters sworn to below. I submit this declaration in support of the above-referenced patent application.
2. Med Five has been selling products to promote health including a four bottle system branded the “Rejuvete Life System”.
3. Bottle One of the Rejuvete Life System, referred to as “Clean Life”, reflects a mouth rinse prepared by dissolving tablets containing EDTA, Lysozyme and Vitamin C in a mouth wash solution. The Clean Life mouth rinse is used twice daily to rinse the mouth and is not ingested. It is intended to kill pathogenic oral bacteria, dissolve plaque and reverse gum disease. It is believed that the EDTA, Lysozyme and Vitamin C act synergistically within the mouth rise and also work in synergy with Bottles Two through Four described below. While Bottle One can be used by itself, the full benefits of the Rejuvete Life System are obtained by using Bottle one in conjunction with Bottles Two through Four.

4. Bottle Two of the Rejuvete Life System, referred to as “Defend Life,” comprises enteric coated tablets containing EDTA, Vitamin C and dimercaptosuccinic acid (“DMSA”). Bottle Two is ingested twice daily. The enteric coating protects the tablet through the stomach and allows the tablet to be dissolved in and be absorbed by the small intestine. Bottle Two is intended to remove toxic metals and plaque from the user’s arteries and tissues. The active ingredients in Bottle Two are believed to work synergistically with each other including to promote the ingredients’ absorption through the intestinal wall. Bottle Two also is believed to work synergistically with Bottles One, Three and Four of the System.

5. Bottle Three of the Rejuvete Life System, referred to as “Renew Life,” comprises gel capsules containing phosphatidylcholine and alpha lipoic acid. Bottle Three is ingested twice daily along with the tablets contained in Bottle Two and capsules contained in Bottle Four. Bottle Three is intended to promote the absorption of Bottle Two ingredients through the intestinal wall, eliminate cholesterol, and improve and protect cell membranes within a variety of tissues, and improve the immune system. The ingredients of Bottle Three are believed to work synergistically with each other and with Bottles One, Two and Four of the System.

6. Bottle Four of the Rejuvete Life System, referred to as “Protect Life,” comprises gel capsules containing extracts of Reishi and Shiitake mushrooms. The capsules of Bottle Four are taken twice daily, are intended to boost the patient’s immune system, and are believed to work synergistically with the dosage forms of Bottles One through Three.

7. More information about the “Rejuvete Life System,” its components and physiological mechanisms, can be found on the Med Five website located at <http://www.medfive.com>.

8. Since mid-2004, Med Five has distributed approximately 15,000 units of the Rejuvete Life System. Med Five, Inc.’s total revenues to date for the Rejuvete Life System is in excess of One Million One Hundred Thousand dollars.


9. At the time Med Five introduced the Rejuvete Life System in April 2004, the market for prophylactic EDTA health supplements was held predominantly by three

Serial No. 10/571,740
Attny. Docket No. 4396-060415
Declaration of Ralph A. Cowden, III
Page 3

companies, all of which offered the supplement in suppository form only. Once introduced, Applicant's RejuvetaLife System captured approximately 12 percent of the market previously held by those selling the EDTA containing suppositories. Med Five's sales of the RejuvetaLife System have grown significantly since then and Med Five assumes its market share has likewise increased.

10. I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: Honolulu, Hawai'i, March 27, 2010.



RALPH A. COWDEN, III